A novel N-methyl, N-phenyl-[6-chloro-2-（4-chlorophenyl）-8-iodoimidazo[1, 2-a]- pyridine-3-yl]acetamide （compound Ⅴ） was synthesized, radiolabelled with 131I and evaluated in vitro. In vitro cell uptake studies sh...A novel N-methyl, N-phenyl-[6-chloro-2-（4-chlorophenyl）-8-iodoimidazo[1, 2-a]- pyridine-3-yl]acetamide （compound Ⅴ） was synthesized, radiolabelled with 131I and evaluated in vitro. In vitro cell uptake studies showed that MDA-MB-231 cells yield four-fold higher specific uptake of [^131I]-compound Ⅵ than MCF-7 cells, corresponding to the increased expression of PBR in MDA-MB-231 cells. Blocking studies significantly reduced the MDA-MB-231 cells uptake of [^131I]-compound Ⅵ. It indicated that [^131I]-compound Ⅵ might be a potential SPECT radioligand for imaging of PBR.展开更多
文摘A novel N-methyl, N-phenyl-[6-chloro-2-（4-chlorophenyl）-8-iodoimidazo[1, 2-a]- pyridine-3-yl]acetamide （compound Ⅴ） was synthesized, radiolabelled with 131I and evaluated in vitro. In vitro cell uptake studies showed that MDA-MB-231 cells yield four-fold higher specific uptake of [^131I]-compound Ⅵ than MCF-7 cells, corresponding to the increased expression of PBR in MDA-MB-231 cells. Blocking studies significantly reduced the MDA-MB-231 cells uptake of [^131I]-compound Ⅵ. It indicated that [^131I]-compound Ⅵ might be a potential SPECT radioligand for imaging of PBR.
